Strona główna
  • Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Progress in Neurotherapeutics and Neuropsychopharmacology: Volume 3, 2008

Progress in Neurotherapeutics and Neuropsychopharmacology: Volume 3, 2008

9780521115612
201,54 zł
181,38 zł Zniżka 20,16 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 181,38 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.
Szczegóły produktu
Cambridge University Press
98825
9780521115612
9780521115612

Opis

Rok wydania
2009
Numer wydania
1
Oprawa
miękka foliowana
Liczba stron
312
Wymiary (mm)
152.00 x 229.00
Waga (g)
460
  • Contributors; 1. Progress in neurotherapeutics and neuropsychopharmacology Jeffrey L. Cummings; 2. Trifusal versus aspirin for the prevention of stroke Antonio Culebras, Javier Borja and Julian Garcia-Rafanell; 3. The Argatroban and tPA stroke study Andrew D. Barreto and James C. Grotta; 4. Use of Selegiline as monotherapy and in combination with Levodopa in the management of Parkinsons disease:: perspectives from the MONOCOMB study Sven E. P?lhagen and Esa Heinonen; 5. Ropinirole 24-h prolonged release in advanced Parkinsons disease:: review of a randomised, double-blind, placebo-controlled study (EASE PD - adjunct study) Kelly E. Lyons and Rajesh Pahwa; 6. Insulin resistance and Alzheimers disease:: pathophysiology and treatment G. Stennis Watson and Suzanne Craft; 7. Targeting Amyloid with Tramiprosate in patients with mild-to-moderate Alzheimers disease P. S. Aisen, R. Briand, D. Saumier, J. Laurin, A. Duong and D. Garceau; 8. Intranasal Zolmitriptan is effective and well-tolerated in acute cluster headache:: a randomized placebo-controlled double-blind crossover study E. Cittadini and P. J. Goadsby; 9. Optimal dosing of immunomodulating drugs:: a dose-comparison study of GA in RRMS Daniel Wynn, Catherine Meyer, Neil Allen and Dennis OBrien; 10. Tetrathiomolybdate versus Trientine in the initial treatment of neurologic Wilsons disease George J. Brewer, Fred Askari, Matthew T. Lorincz, Martha Carlson, Michael Schilsky, Karen J. Kluin, Peter Hedera, Paolo Moretti, John K. Fink, Roberta Tankanow, Robert B. Dick and Julia Sitterly; 11. Randomized clinical trials of Pregabalin for neuropathic pain:: methods, results, and implications Robert H. Dworkin, Rajbala Thakur, Teresa Griesing, Uma Sharma and James P. Young; 12. Effect of Methylphenidate in patients with acute traumatic brain injury:: a randomized clinical trial Hossein A. Khalili and Kamyar Keramatian; 13. Improvement in speeded cognitive processing after anti-epileptic drug withdrawal - a controlled study in mono-therapy patients Erik Hessen, Morten I. Lossius, Ivar Reinvang and Leif Gjerstad; 14. A randomized-controlled trial of bilateral rTMS for treatment-resistant depression Paul B. Fitzgerald; 15. Serotonin related genes affect antidepressant treatment in obsessive-compulsive disorder F. Van Nieuwerburgh, D. Deforce and D. A. J. P. Denys; 16. Night eating syndrome and results from the first placebo-controlled trial of treatment, with the SSRI medication, Sertraline:: implications for clinical practice John P. OReardon Karen E. Groff, Albert J. Stunkard and Kelly C. Allison; 17. Modafinil:: a candidate for pharmacotherapy of negative symptoms in schizophrenia John H. Peloian and Joseph M. Pierre; 18. New approaches to treatment of schizophrenia by enhancing N-methyl-D-aspartate neurotransmission Guochuan Emil Tsai; Subject index; Author index.
Komentarze (0)

  • Często kupowane razem

    Brak dostępnych produktów